Katholieke Universiteit Leuven, Ku Leuven R&d

Vib Vzw

Vrije Universiteit Brussel

Lujia Zhou

Bart De Strooper

Serge Muyldermans

Els Marjaux

Wim Annaert

Patrik Verstreken

Joseph McInnes

The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.

Targeting synaptogyrin-3 in tauopathy treatment

Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Single domain antibodies capable of modulating BACE activity

The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

BACE1 inhibitory antibodies

Growing community of inventors

Leuven, Belgium

Lujia Zhou